Clinical Trials Logo

Clinical Trial Summary

his study aims to address two key aspects - part 1: the suitability of selecting a specific sampling site for BHB measurement in patients and research, as well as potential differences between capillary and venous blood measurements. Additionally, the study will delve into the effects of ketosis on EPO concentrations, sex hormones levels, and hemodynamic markers and blood pressure - part 2. This investigation will utilize blood samples collected during part 1, including acute effects, as well as samples taken on day 7 and day 14 during which period participants are exposed to intermittent ketosis.


Clinical Trial Description

Aim and Perspective: The primary objective of this study - part 1 - is to ascertain: The agreement between estimates of beta-hydroxybutyrate (BHB) in capillary and venous blood and whether this agreement is influenced by the level of BHB. The agreement in BHB measurements between finger and earlobe capillary samples. The agreement in BHB measurements between venous estimates obtained through a point-of-care device (KetoSure) and full blood estimates obtained through hydrophilic interaction liquid chromatography tandem mass spectrometry (HLCMS). The central aim of the study - part 2 - is to investigate: The impact of ketosis on short-term and long-term erythropoietin (EPO) levels. The resulting effects of EPO on erythropoiesis and iron metabolism during a two-week period of intermittent ketosis. The effects of ketosis and sex hormones including derived factors The effects of ketosis on hemodynamic markers and blood pressure The study aims to determine the appropriateness of selecting a specific sampling site for BHB measurement in both patient care and research. Additionally, it seeks to identify any differences between BHB measurements from capillary and venous blood samples. The study will also examine the concordance between the KetoSure point-of-care-test (POCT) device and the established gold standard, offering insight into any discrepancies arising from electrochemical estimations and HLCMS. Accurate BHB measurement is crucial in clinical and experimental settings. Firstly, precise BHB quantification can inform clinical decision-making for conditions such as suspected hyperinsulinemia, uncertain etiology hypoglycemia, and diabetic ketoacidosis. Secondly, given the extensive research on BHB inference and ketones in recent years, the credibility of these studies heavily hinges on the precision of measurements concerning sample type and sampling site selection. Additionally, during part 2 of the study, the effects of ketosis on EPO concentrations, sex hormone levels, hemodynamic markers, and blood pressure measurements will be explored. These analyses will be conducted using blood samples collected during part 1 (acute effects) as well as on day 7 and day 14, when participants experience intermittent ketosis. Analytical Approach: Following a visual assessment of graphical linearity representation, differences will be calculated using the paired t-test, agreement determined using the Bland-Altman plot, and correlations assessed using Pearson's r. Further calculations will employ Lin's concordance correlation coefficient of absolute agreement. For comparisons across observations in parts 1 and 2, an analysis equivalent to repeated measurements ANOVA will be applied. No imputation of missing data will be conducted, and steps will be taken to ensure data completeness before participants leave the research facilities. Sample Size and Power Calculation: Given the absence of prior studies on BHB agreement data, our study's sample size calculations are based on relevant literature. Citing Boyd et al., and considering correlated glucose estimates, a sample size of 13 participants will provide sufficient statistical power (alpha = 0.05, beta = 20%) to detect a difference of 0.58 mM in glucose estimates between capillary and venous blood samples (SD = 0.68 mM). A sample size of 20 participants is justifiably required to detect a clinically significant difference of 1 mM (SD = 1.5) under the same parameters. Consequently, we will include 16 patients in our study, aligning with similar projects and justified sample size for part 2. Collection of New Biological Material: A total of 150 mL of blood will be drawn, including incidental spillage from repeated sampling through an indwelling catheter in part 1. No spillage is expected in part 2 as blood sampling occurs only twice in an outpatient setting, with subsequent laboratory analysis. Purpose of Storage: All biological samples will be stored for the entire data collection period and 18 months thereafter for bulk analysis. Storage will be at -80 ºC. A research biobank will be established to analyze samples not analyzed on the study day, with surplus material preserved for future research. Handling of Patient Information: Access to participants' electronic patient records, limited to the laboratory results section, is included in the consent for practical reasons. Only routinely obtained treatment-related information necessary for analysis will be accessed. Any information obtained before consent will be shared with the investigator. Data Privacy and Sharing: Data will be pseudonymized during analysis, with de-identification codes retained by the primary investigator. Data access will be restricted to investigators until final analysis. Upon anonymization, other investigators will gain access. After publication, all data will be open accesible upon reasonably request. However, consideration to make data available to public scrutiny is under consideration. Financial Information: The study is initiated and financed by the primary investigator, Henrik Holm Thomsen. Funding originates from independent research funds within the Department of Internal Medicine, Regional Hospital Viborg. Additional external funding will be pursued for study expenses only, excluding investigator salaries. Financial transactions follow the research practices of the Central Denmark Region and Regional Hospital Viborg. Research investigators and collaborators have no financial interests in the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06053138
Study type Interventional
Source Central Jutland Regional Hospital
Contact Henrik H Thomsen, Ph.D.
Phone +4550721835
Email henrik.holm.thomsen@midt.rm.dk
Status Recruiting
Phase N/A
Start date August 24, 2023
Completion date February 2024

See also
  Status Clinical Trial Phase
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04817176 - MI-CBT Adherence Program for Lifestyle Interventions in Older Adults Early Phase 1
Completed NCT04565444 - Ketones and Muscle Protein Synthesis N/A
Not yet recruiting NCT06418074 - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity N/A
Not yet recruiting NCT03954665 - Ketone Supplementation and Exercise Performance N/A
Active, not recruiting NCT06097754 - Intermittent Exogenous Ketosis (IEK) at High Altitude N/A
Terminated NCT03790436 - Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet N/A
Completed NCT03299543 - Comparison Between Breath Acetone and Blood Beta-Hydroxybutyrate
Recruiting NCT04004676 - Ketone Supplementation, Glycogen Replenishment and Time Trial Performance Following Glycogen Lowering Exercise N/A
Not yet recruiting NCT03659825 - Ketone Esters for Optimization of Cognitive Performance in Hypoxia N/A
Active, not recruiting NCT04156477 - Markers of Appetite Regulation During Exogenous Ketosis N/A
Completed NCT04130724 - Characterization of a Portable Solid-State Breath Acetone Testing Device for Real-Time Ketosis Status
Recruiting NCT04594265 - Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure Phase 2
Not yet recruiting NCT04576026 - Exogenous Ketone Supplementation and Cognitive Function During Exercise N/A
Completed NCT05558488 - The Effect of a Meatless,Keto Restrictive Diet on Body Composition,Strength Capacity,Oxidative Stress,Immune Response N/A
Recruiting NCT03564002 - Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity
Completed NCT04309214 - Market Research - Acceptability Study for New MCT Fat Products N/A
Completed NCT05588427 - Effect of Ketone Ester Supplementation on Hypoxic Tolerance N/A
Recruiting NCT05656339 - Metabolic Effects of Whey Protein Supplementation After Fasting in Volunteers N/A